Citi analyst Joanne Wuensch downgraded Baxter to Sell from Neutral with a price target of $17, down from $19. The company faces a back-half weighted year and is searching for a CFO, the analyst tells investors in a research note. Citi downgrades Baxter to Sell, saying the rest of medical technology valuations are \"dipping into value territory,\" creating better options.
